“Companies need to play a leadership in helping labs to adopt the most efficient implementations of new technologies” – Interview with Dr. Attila Berces, Founder of Omixon

28/06/2018

This interview is part of a series that we are conducting with Key Opinion Leaders, Experts and Business Managers within the HLA field. This time, Mr. Attila Berces, Ph.D., Founder and Chairman of Omixon shares his thoughts about future technology improvements. We hope this series will shed a light...

NGS Workflow in a Low Throughput Lab

20/06/2018

In her EFI 2018 User Group Meeting presentation, Dr. Sonja Verheyden (UZ Brussels) talked about issues that a small, low throughput lab can face, why they consider next-generation sequencing for HLA typing and how to make NGS cost-effective in a lab like UZB? You can download her presentation...

Questions of Fragmentation, Size Selection and Read Length

11/06/2018

In her EFI 2018 User Group Meeting presentation, Beatrice Bardy (EFS Grenoble) discussed issues about length of fragments and their influence on result quality, including fragmentation and size selection, ambiguities and false novelties using the Holotype HLA protocol since 2016. Download the full presentation here…

Omixon Announce Partnership with Dilen s.r.o.

30/05/2018

Omixon announce today a new partnership with Dilen s.r.o. appointed as our exclusive distributor for all our products in Kazakhstan. Dilen s.r.o. will distribute and provide technical support for all our products to existing and new customers in the country. Dilen s.r.o., founded in 1994 and has its headquarters in Prague,...

Holotyping Through Venice – Omixon at the Annual EFI Conference

28/05/2018

Omixon rocked the EFI meeting again, though we almost couldn’t make it to Venice in time, due to airport strikes and flight cancellations. Getting to Venice is never easy, but at least we had the opportunity to enjoy the city’s magnificent atmosphere by water taxis and speedboats – something...